Bain Capital Life Sciences Investors, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Bain Capital Life Sciences Investors, LLC reported 22 stock positions worth $798.5 million. Its top holding was Newamsterdam Pharma (NAMS) at 24.3% of the portfolio, followed by Cidara Therapeutics (CDTX, 15.3%) and Nuvalent Class A (NUVL, 13.8%). Compared with Q1 2025, it sold out of 1, added to 3 and reduced 2. The biggest buy was Cidara Therapeutics (CDTX, shares +256%) and the biggest sale Disc Medicine (IRON, shares −41%).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001703031
- Portfolio Value
- $798.5M (Q2 2025)
- SEC Filing
- 0000950123-25-008312 ↗ filed Aug 14, 2025
Holdings Value
Holdings 22 stocks · $798.5M
| NAMS Newamsterdam Pharma Co. NV | 24.31% | 10,719,110 | $194.1M | No change |
| CDTX Cidara Therapeutics Inc. | 15.26% | 2,500,680 | $121.8M | Add +255.7% |
| NUVL Nuvalent Inc. Class A | 13.83% | 1,447,267 | $110.4M | No change |
| PHVS Pharvaris NV | 7.28% | 3,303,381 | $58.1M | No change |
| DNTH Dianthus Therapeutics Inc. | 5.79% | 2,482,250 | $46.2M | Reduce -7.7% |
| SVRA Savara Inc. | 5.03% | 17,600,621 | $40.1M | No change |
| SLDB Solid Biosciences Inc. | 4.83% | 7,911,669 | $38.5M | No change |
| IRON Disc Medicine Inc. | 3.87% | 583,500 | $30.9M | Reduce -40.7% |
| OLMA Olema Pharmaceuticals Inc. | 3.65% | 6,843,954 | $29.2M | No change |
| RPID Rapid Micro Biosystems Inc. Class A | 3.64% | 8,434,560 | $29.1M | No change |
| UPB Upstream Bio Inc. | 3.35% | 2,439,538 | $26.8M | Add +6.3% |
| CABA Cabaletta Bio Inc. | 1.84% | 9,677,125 | $14.7M | Add +250.5% |
| TNGX Tango Therapeutics Inc. | 1.74% | 2,712,008 | $13.9M | No change |
| ANNX Annexon Inc. | 1.58% | 5,249,069 | $12.6M | No change |
| KYTX Kyverna Therapeutics Inc. | 1.30% | 3,368,370 | $10.3M | No change |
| AVIR Atea Pharmaceuticals Inc. | 1.12% | 2,485,638 | $8.9M | No change |
| XLO Xilio Therapeutics Inc. | 0.39% | 4,566,817 | $3.1M | No change |
| IPSC Century Therapeutics Inc. | 0.38% | 5,410,361 | $3.0M | No change |
| MERSANA THERAPEUTICS INC | 0.32% | 8,663,673 | $2.6M | No change |
| CCCC C4 Therapeutics Inc. | 0.20% | 1,111,910 | $1.6M | No change |
| IVVD Invivyd Inc. | 0.16% | 1,799,595 | $1.3M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.13% | 563,859 | $1.1M | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $800K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 100,000 | $800K | No change |
Total filed on the 13F, all lines: $799.3M.
Portfolio Sells Q1 2025 → Q2 2025
Portfolio Buys Q1 2025 → Q2 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $1.7B | KLRA, HTFL, NAMS, SVRA, ALKS |
| Q1 2026 | 19 | $1.1B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q4 2025 | 18 | $1.3B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q3 2025 | 20 | $1.5B | HTFL, NAMS, CDTX, PHVS, OLMA |
| Q2 2025 | 22 | $798.5M | NAMS, CDTX, NUVL, PHVS, DNTH |
| Q1 2025 | 23 | $675.0M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q4 2024 | 25 | $848.7M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q3 2024 | 23 | $960.5M | NUVL, NAMS, IRON, DNTH, SVRA |
| Q2 2024 | 24 | $910.0M | NUVL, NAMS, IRON, DNTH, PHVS |
| Q1 2024 | 25 | $1.2B | NAMS, NUVL, DNTH, IRON, KYTX |